Pilot Configuration
Pilot Phase (Scoped Evaluation)
Up to 12 weeksTypical scope: multi-country, weekly updates, multiple categories
- Real data from real sources
- Live dashboards or export feeds
- Validate scope, refresh cadence, quality
- Fixed price, no ongoing commitment
Most teams start here to validate fit before expanding.
Now, schedule a short call below to confirm scope and start the pilot, or build something new.
or email us at paul@jsonify.co
Data sources are the websites and apps where information will be collected from. These can be changed or expanded at any time. This is turned into data rows.
| id | Source | DocumentTitle | Drug | NegotiatedPrice | Manufacturer | EffectiveDate | Status | Summary | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 |
|
Medicare Part D Negotiated Price Update Bulletin | Eliquis (apixaban) 5 mg | $412.50 | Bristol-Myers Squibb | Feb 2, 2026 | Published | CMS bulletin noting updated negotiated reimbursement benchmark for apixaban under recent Part D pricing rule; reflects increased rebates affecting beneficiary cost share projections. ... show all |
||
| 2 |
|
Advisory: New Labeling Guidance for Oncology Agents | Lumakras (sotorasib) 960 mg | $18,950.00 | Amgen | Feb 1, 2026 | Guidance | Labeling guidance issued for KRAS G12C inhibitor; includes recommended post-marketing study requirements and safety monitoring; pricing example cited from manufacturer submission. ... show all |
||
| 3 |
|
PBM Quarterly Pricing Trends Report | Humira (adalimumab) 40 mg | $1,725.00 | AbbVie | Jan 31, 2026 | Analysis | PBM report shows increased net-pricing concessions and shifting formularies; biosimilar uptake cited as driver of reduced net cost for adalimumab in commercial lines. ... show all |
||
| 4 |
|
Distribution Margin Pressure: February Brief | Keytruda (pembrolizumab) 100 mg | $14,200.00 | Merck | Feb 3, 2026 | Report | Industry analysis highlights margin compression across specialty distribution; negotiated buy-and-bill reimbursement trends for immuno-oncology agents discussed. ... show all |
||
| 5 |
|
Market Snapshot: Top 20 Specialty Drug Prices | Trikafta (elexacaftor/tezacaftor/ivacaftor) | $32,400.00 | Vertex | Feb 4, 2026 | Snapshot | Statistical snapshot of list vs. negotiated prices for cystic fibrosis therapies; data show negotiated discounts vary widely by payer and year-to-year contracts. ... show all |
||
| 6 |
|
Health Products Consumer Price Sensitivity Study | Xarelto (rivaroxaban) 20 mg | $289.00 | Bayer | Feb 3, 2026 | Survey | Consumer survey finds high price sensitivity for chronic oral anticoagulants; Nielsen models estimate copay assistance alters adherence patterns. ... show all |
||
| 7 |
|
Global PBM Competitive Landscape Report | Ozempic (semaglutide) 1.0 mg | $975.00 | Novo Nordisk | Jan 30, 2026 | Report | Market research on PBM strategies notes preferred formulary placements and step-therapy programs for GLP-1s; negotiated net prices vary by region. ... show all |
||
| 8 |
|
Supply Chain Alert: API Shortage Impact | Valproate (sodium valproate) 500 mg | $48.75 | Generic Consortium | Feb 2, 2026 | Alert | IHS alert on active pharmaceutical ingredient shortages driving temporary negotiated price increases and allocation measures across wholesalers and PBMs. ... show all |
||
| 9 |
|
Policy Watch: Drug Pricing Transparency Rules | Jardiance (empagliflozin) 25 mg | $210.00 | Boehringer Ingelheim | Feb 1, 2026 | News | Coverage of new transparency mandates requiring PBMs to publish negotiated rates; commentary on potential market impacts and patient cost sharing. ... show all |
||
| 10 |
|
Investor Presentation: Specialty Portfolio Pricing Update | Nucala (mepolizumab) 100 mg | $4,350.00 | GSK | Feb 3, 2026 | Presentation | Investor deck lists updated list and negotiated price ranges for respiratory biologics following recent contracting cycles with large PBMs. ... show all |
||
| 11 |
|
Contracting Notice: Updated Rebate Terms | Ibrance (palbociclib) 125 mg | $9,150.00 | Pfizer | Feb 4, 2026 | Notice | Manufacturer notice to payers outlining revised rebate schedule and performance-based contracting options tied to progression-free survival metrics. ... show all |
||
| 12 |
|
Pricing Update: Biosimilar Adoption Initiatives | Enbrel (etanercept) 50 mg | $1,100.00 | Amgen | Feb 2, 2026 | Update | Company update on pricing and contracting incentives to support biosimilar and originator market positioning within PBM formularies. ... show all |
||
| 13 |
|
Medicaid Drug Rebate Program: Guidance Amendment | Spiriva (tiotropium) 18 mcg | $36.40 | Boehringer Ingelheim | Feb 3, 2026 | Guidance | CMS amends guidance on best-price calculations impacting state Medicaid rebates; example pricing scenarios for inhaled bronchodilators included. ... show all |
||
| 14 |
|
Approval Letter: New Indication Pricing Disclosure | Enhertu (trastuzumab deruxtecan) 5.4 mg/kg | $22,500.00 | AstraZeneca/Daiichi Sankyo | Feb 1, 2026 | Approval | Approval letter for expanded oncology indication with accompanying sponsor-submitted wholesale acquisition cost and example negotiated price ranges. ... show all |
||
| 15 |
|
PBM Playbook: Formulary Steering Tactics | Dupixent (dupilumab) 300 mg | $3,650.00 | Sanofi/Regeneron | Feb 4, 2026 | Guide | Practical guide describing step edits, prior authorization criteria, and negotiated rebate structures used to control biologic spend. ... show all |
||
| 16 |
|
Wholesaler Pricing Volatility Brief | Remicade (infliximab) 100 mg | $1,980.00 | Janssen | Feb 2, 2026 | Analysis | Analysis of negotiated buy-and-bill reimbursement variability and effects of biosimilar entrants on contracted prices for infliximab products. ... show all |
||
| 17 |
|
Price Index: Oral Oncology Agents | Gleevec (imatinib) 400 mg | $5,420.00 | Novartis | Jan 31, 2026 | Index | Compiled index showing year-over-year negotiated price movements for oral oncology agents across commercial and Medicare plans. ... show all |
||
| 18 |
|
Pharmacy Shopper Insights Report | Prolia (denosumab) 60 mg | $1,425.00 | Amgen | Feb 3, 2026 | Report | Shopper behavior analysis indicating patients switching pharmacies for lower negotiated copays and adherence impact on osteoporosis biologics. ... show all |
||
| 19 |
|
US PBM Fee Model Study | Symbicort (budesonide/formoterol) 160/4.5 mcg | $74.99 | AstraZeneca | Feb 2, 2026 | Study | Study detailing PBM administrative fee arrangements, DIR fee trends, and impact on net paid price for respiratory maintenance inhalers. ... show all |
||
| 20 |
|
Forecast: Sterile Injectable Cost Pressures | Vancomycin IV 1 g | $12.50 | Generic Multiple | Feb 4, 2026 | Forecast | IHS forecast projects continued pricing pressure on sterile injectables due to contract consolidation and manufacturing capacity shifts. ... show all |
||
| 21 |
|
Analysis: Impact of Copay Accumulator Policies | Xgeva (denosumab) 120 mg | $4,980.00 | Amgen | Feb 1, 2026 | Analysis | Examination of copay accumulator adoption by payers and PBMs and its downstream effect on patient out-of-pocket for high-cost injectables. ... show all |
||
| 22 |
|
Formulary Access Update: Respiratory Franchise | Nucala (mepolizumab) 100 mg | $4,150.00 | GSK | Feb 4, 2026 | Update | Company release on updated contracting outcomes with national PBMs to secure preferred formulary placement for eosinophilic asthma therapy. ... show all |
||
| 23 |
|
Value-Based Contracting Whitepaper | Xeljanz (tofacitinib) 5 mg | $1,350.00 | Pfizer | Jan 30, 2026 | Whitepaper | Whitepaper describing risk-sharing contract structures and sample negotiated price matrices tied to clinical endpoints for RA therapies. ... show all |
||
| 24 |
|
Pipeline Pricing Strategy Memo | Tezepelumab 210 mg | $7,800.00 | Amgen | Feb 2, 2026 | Internal Memo | Memo outlining preliminary pricing and contracting assumptions for late-stage asthma biologic ahead of launch, including PBM negotiation scenarios. ... show all |
||
| 25 |
|
CMS Transparency Dashboard Update | Ozempic (semaglutide) 1.0 mg | $825.00 | Novo Nordisk | Feb 3, 2026 | Published | Dashboard refresh includes recent commercial aggregated negotiated price estimates and payer-level anonymized ranges for diabetes therapies. ... show all |
||
| 26 |
|
Drug Safety Communication: REMS and Cost Considerations | Zolgensma (onasemnogene abeparvovec) | $1,850,000.00 | Novartis | Feb 1, 2026 | Safety Communication | Safety communication reiterates REMS requirements for gene therapy; sponsor provided representative negotiated contracting structures for government payers. ... show all |
||
| 27 |
|
PBM Contracting Trends: February Brief | Entresto (sacubitril/valsartan) 200 mg | $295.00 | Novartis | Feb 4, 2026 | Brief | Brief identifies rising use of indication-based pricing clauses and rebates tied to hospitalization reduction metrics for heart failure drugs. ... show all |
||
| 28 |
|
Retail Pharmacy Margin Report | Adderall XR (mixed amphetamine salts) 20 mg | $68.00 | Teva | Feb 2, 2026 | Report | Report on dispensing margins, DIR fee clawbacks, and negotiated reimbursement variability affecting community pharmacies dispensing stimulants. ... show all |
||
| 29 |
|
Trend Chart: Biosimilar Price Convergence | Zarxio (filgrastim-sndz) 300 mcg | $285.00 | Sandoz | Feb 3, 2026 | Chart | Chart documenting narrowing net price differentials between originator and first-wave biosimilars across hospital and outpatient settings. ... show all |
||
| Looking for more? Great news − this is just a small sample. Jsonify production workflows process anywhere from tens of thousands to millions of real data rows per run! | ||||||||||
Filters
Total Regulatory Documents Analyzed
Distribution of Drug Pricing Strategies
Top 10 Emerging PBM Trends
Total Competitor Drug Pricing Strategies Reviewed
Historical Average Drug Prices by Class
Key Observations on Pricing Strategies
Emerging Trends in Pharmacy Benefit Management Over Time
Latest Industry Analyst Reports
| Source | Report Title | Key Findings | Publication Date |
|---|---|---|---|
|
|
2026 Pharmacy Pricing Trends | Increased focus on transparency and cost-sharing strategies. | 2026-01-15 |
|
|
PBM Oversight Report 2026 | Regulations tightening around formulary management practices. | 2026-01-10 |
|
|
Drug Approval and Pricing Strategy Analysis | New generics expected to decrease prices of branded drugs. | 2026-01-20 |
|
|
2026 Industry Pricing Trends | Shift towards value-based pricing models gaining traction. | 2026-01-05 |
|
|
2026 Market Outlook for Pharmaceuticals | Projected growth in specialty drug spending. | 2026-01-12 |
|
|
Trends in Drug Pricing 2026 | Average price increase of 5% for top medications. | 2026-01-25 |
|
|
The Future of Pharmacy Benefit Management | Emerging trends in integrated care models highlighted. | 2026-01-30 |
|
|
Consumer Insights on Prescription Drugs | Increased patient engagement in drug selection noted. | 2026-01-28 |
New Drug Pricing Introductions Over Time
Top 5 Competitors by Market Share
Regulatory Changes Impacting PBM
| Source | Regulation | Impact Area | Effective Date | Notes |
|---|---|---|---|---|
|
|
New PBM Transparency Rules | Pricing Transparency | 2026-01-01 | Requires PBMs to disclose rebate structures. |
|
|
Affordable Care Act Amendments | Coverage Requirements | 2026-03-15 | Expands coverage for certain preventive medications. |
|
|
Drug Price Control Initiatives | Price Regulation | 2026-06-30 | Implements caps on drug price increases. |
|
|
PBM Market Consolidation Report | Market Dynamics | 2026-02-01 | Notes increasing concentration among major PBMs. |
|
|
2026 Pharmaceutical Industry Outlook | Market Trends | 2026-04-10 | Predicts shifts in specialty drug pricing strategies. |
|
|
Trends in Drug Pricing Strategies | Competitive Pricing | 2026-02-20 | Highlights competitive responses to new regulations. |
|
|
Emerging PBM Models | Business Strategy | 2026-05-05 | Discusses innovative PBM service models. |
|
|
Consumer Responses to Drug Pricing | Consumer Behavior | 2026-07-15 | Examines how consumers are reacting to price changes. |
Source Contribution to Insights
Loading...
Loading...
Radar continuously monitors your selected web sources and alerts you the moment something changes.
+7
Data connections determine where the collected data will be delivered. You can add, remove, or change connections at any time.